New BIO chairwoman: Biotechnology has proud story to tell

04/29/2013 | Washington Post, The

The biotechnology sector needs to share its health care accomplishments with consumers and lawmakers, highlighting the contributions it makes through drug development, newly elected BIO chairwoman Rachel King said. "Most people have probably benefited or know someone who has benefited. We need to communicate, as part of that, that to get to those new medicines takes a long time and a lot of investment," she said. King, the president and CEO of GlycoMimetics, said the FDA's efforts to hasten the approval process are crucial for limiting investor uncertainty and bringing new drugs to patients.

View Full Article in:

Washington Post, The

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC